Biovotec as

Rose Pharma LLC

Mannkind Corporation

Enda Kenny

Ralf Schmidt

Henri-Pierre Suso

Andrea Hawe

Richard J Warburg

Eva Keilhauer

Olimpia Popko

Grayson Walker Stowell

Marshall L Grant

Matthias Schnabelrauch

Peter Richardson

Annika Wartenberg

Paul Barham

Per Hellstrom

Scott Daniels

Anthony Smithson

Stephanie Greene

Provided herein is a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 μm for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. Further provided are pharmaceutical compositions, wound dressings and implantable medical devices including the micronized ESM-containing particles for use in said treatments. Still further provided are methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices including the same.

Micronized eggshell membrane particles and the use thereof to promote the healing of wounds

The invention provides a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 μm for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. The invention further provides pharmaceutical compositions, wound dressings and implantable medical devices comprising the micronized ESM-containing particles for use in said treatments. The invention still further provides methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices comprising the same.

Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.

Methods of treatment with stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

The invention provides a three dimensional (3D), porous, biodegradable and biocompatible tissue engineering scaffold, wherein at least 25% w/w of the scaffold is particulate egg shell membrane (ESM) distributed substantially uniformly therein and the scaffold is essentially dry. Methods for preparing the same by freeze-drying and cryogelation and the use thereof in methods of tissue engineering and to promote the healing of wounds are also provided.

Tissue engineering scaffolds comprising particulate egg shell membrane

The invention provides a dry biocompatible film comprising at least one film forming material and particulate egg shell membrane (ESM), wherein said particulate ESM is distributed substantially uniformly in and/or on the film and wherein said film, or portion thereof, disintegrates upon contact with a wound or an exudate thereof. The invention further provides methods for preparing the films of the invention and the uses thereof in methods to promote the healing of wounds.

Dry biocompatible disintegratable films for delivering particulate egg shell membrane to a wound

A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.

Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome

Growing community of inventors

Dublin, Ireland

Enda Kenny